(−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid exerts anti-tumour effects against uveal melanoma through PI3K/AKT pathway. (3rd April 2021)
- Record Type:
- Journal Article
- Title:
- (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid exerts anti-tumour effects against uveal melanoma through PI3K/AKT pathway. (3rd April 2021)
- Main Title:
- (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid exerts anti-tumour effects against uveal melanoma through PI3K/AKT pathway
- Authors:
- Kang, Hao
Ling, Feng
Xin, Xiangyang
Ping, Li - Abstract:
- Abstract: Purpose: Uveal melanoma is the most common primary intraocular tumour in adults. There is no standard adjuvant treatment to prevent metastasis and no effective therapy in the metastatic setting. (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid (QA) is a new compound isolated from the endophytic fungus Penicillium sp.FJ-1 of Avicennia marina, with potent activities to inhibit the PI3K. Our work further investigated effects of QA against uveal melanoma and explored its underlying mechanisms. Methods: MP65 cells were treated with QA at different concentrations. CCK-8 assay was used to detect effects of QA on cell viability. PI staining was used to detect cell cycle arrest. Tumour model was established by injecting MP65 cells into nude mice subcutaneously. Tumour-bearing mice were divided into three groups (5 mice per group). Mice were treated with QA (5 or 10 mg/kg) or saline by intraperitoneal injection five times per week. RT-qPCR and western blot were used to detect the expression of genes and proteins, respectively. Results: QA significantly inhibited the proliferation of uveal melanoma cells and induced the cell cycle arrest as well as autophagy. Moreover, QA treatment significantly slowed tumour growth of uveal melanoma, shown by decreased tumour volume and weight. Furthermore, QA treatment markedly decreased the protein expression of p-PI3K and p-AKT in tumour tissues. Conclusions: Our data provided scientific rationale to develop QA as a promisingAbstract: Purpose: Uveal melanoma is the most common primary intraocular tumour in adults. There is no standard adjuvant treatment to prevent metastasis and no effective therapy in the metastatic setting. (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid (QA) is a new compound isolated from the endophytic fungus Penicillium sp.FJ-1 of Avicennia marina, with potent activities to inhibit the PI3K. Our work further investigated effects of QA against uveal melanoma and explored its underlying mechanisms. Methods: MP65 cells were treated with QA at different concentrations. CCK-8 assay was used to detect effects of QA on cell viability. PI staining was used to detect cell cycle arrest. Tumour model was established by injecting MP65 cells into nude mice subcutaneously. Tumour-bearing mice were divided into three groups (5 mice per group). Mice were treated with QA (5 or 10 mg/kg) or saline by intraperitoneal injection five times per week. RT-qPCR and western blot were used to detect the expression of genes and proteins, respectively. Results: QA significantly inhibited the proliferation of uveal melanoma cells and induced the cell cycle arrest as well as autophagy. Moreover, QA treatment significantly slowed tumour growth of uveal melanoma, shown by decreased tumour volume and weight. Furthermore, QA treatment markedly decreased the protein expression of p-PI3K and p-AKT in tumour tissues. Conclusions: Our data provided scientific rationale to develop QA as a promising anti-tumour agent against uveal melanoma. … (more)
- Is Part Of:
- Cutaneous and ocular toxicology. Volume 40:Number 2(2021)
- Journal:
- Cutaneous and ocular toxicology
- Issue:
- Volume 40:Number 2(2021)
- Issue Display:
- Volume 40, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 40
- Issue:
- 2
- Issue Sort Value:
- 2021-0040-0002-0000
- Page Start:
- 119
- Page End:
- 124
- Publication Date:
- 2021-04-03
- Subjects:
- (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) quinic acid -- uveal melanoma -- autophagy -- PI3K/AKT
Dermatotoxicology -- Periodicals
Ocular toxicology -- Periodicals
Ocular pharmacology -- Periodicals
Dermatopharmacology -- Periodicals
Toxicology -- Periodicals
615.9 - Journal URLs:
- http://informahealthcare.com/journal/cot ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/15569527.2021.1914074 ↗
- Languages:
- English
- ISSNs:
- 1556-9527
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3506.146900
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17020.xml